Alliance for Clinical Trials in Oncology

Open enrollment with an early-phase pipeline tilt

According to ClinicalTrials.gov-derived indexes, Alliance for Clinical Trials in Oncology sits in the top decile of US sponsors by registered trial count (#80 of 15,742 sponsors by registered trial count).

446 total trials 29 currently recruiting 346 completed early-phase tilt top decile by trial count

Alliance for Clinical Trials in Oncology: 446 sponsored US clinical trials, 29 recruiting.

Alliance for Clinical Trials in Oncology sponsors 446 registered US clinical trials on ClinicalTrials.gov, 29 of them currently recruiting, and 346 completed. 142 of these trials are in Phase 3-4 (later-stage) and 235 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Breast Cancer, with 19 trials.

Top-decile sponsor footprint

Alliance for Clinical Trials in Oncology ranks in the top decile of sponsors by registered trial count (#80 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Trial completion reliability score

C 69/100

346 of 377 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (91.8%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.

Open and recent trials

446 total, page 4 of 9

COMPLETED Phase 2

Erlotinib and Gemcitabine With or Without Panitumumab in Treating Patients With Metastatic Pancreatic Cancer

NCT00550836
TERMINATED Phase 3

Chemotherapy or Observation in Treating Patients With Early Stage Non-Small Cell Lung Cancer

NCT00863512
COMPLETED Phase 2

Docetaxel, Carboplatin, Trastuzumab, and Lapatinib in Treating Patients With Early Stage Breast Cancer

NCT00820872
COMPLETED

Acute Pain Caused by Paclitaxel in Patients With Cancer

NCT00860041
COMPLETED Phase 2

Panitumumab, Docetaxel, Cisplatin, Radiation Therapy, and Surgery in Treating Patients With Newly Diagnosed, Locally Advanced Esophageal Cancer or Cancer of the Gastroesophageal Junction

NCT00757172
COMPLETED Phase 2

Pemetrexed, Carboplatin, and Bevacizumab as First-Line Therapy in Treating Older Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer

NCT00798603
COMPLETED

Study of Tumor Samples in Patients Undergoing Treatment for Gastrointestinal Stromal Tumors on Clinical Trial ACOSOG-Z9001

NCT00954655
COMPLETED Phase 2

Paclitaxel Albumin-Stabilized Nanoparticle Formulation, Gemcitabine, and Bevacizumab in Treating Patients With Metastatic Breast Cancer

NCT00662129
COMPLETED Phase 3

American Ginseng in Treating Patients With Fatigue Caused by Cancer

NCT00719563
TERMINATED Phase 2

Radiation Therapy or Observation After Chemotherapy in Treating Patients With Stage IV Non-Small Cell Lung Cancer

NCT00776100
COMPLETED Phase 2

Bevacizumab and Sorafenib in Treating Patients With Recurrent Glioblastoma Multiforme

NCT00621686
COMPLETED

Study of Tumor Samples From Patients With Lung Cancer

NCT00900328
COMPLETED Phase 2

Bevacizumab and Temozolomide or Bevacizumab and Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Carboplatin in Treating Patients With Stage IV Malignant Melanoma That Cannot Be Removed by Surgery

NCT00626405
COMPLETED Phase 3

Laparoscopic-Assisted Resection or Open Resection in Treating Patients With Rectal Cancer

NCT00726622
COMPLETED

Biomarkers in Predicting Response in Patients With Early-Stage Non-Small Cell Lung Cancer Previously Treated With Adjuvant Chemotherapy

NCT01294280
COMPLETED

Studying Tissue Samples From Women Who Underwent Chemotherapy for Lymph Node-Positive Stage II or Stage IIIA Breast Cancer on Clinical Trial CLB-9741 or CLB-9344

NCT00897026
COMPLETED Phase 2

Galiximab in Treating Patients With Relapsed or Refractory Hodgkin's Lymphoma

NCT00516217
COMPLETED Phase 3

Pregabalin in Treating Women With Hot Flashes

NCT00702949
COMPLETED

Identifying Cancer Genes in in Blood and Bone Marrow Samples From Patients With Acute Myeloid Leukemia

NCT00897182
COMPLETED Phase 3

Duloxetine in Treating Peripheral Neuropathy Caused by Chemotherapy in Patients With Cancer

NCT00489411
COMPLETED Phase 2

Rituximab and Denileukin Diftitox in Treating Patients With Previously Untreated Stage III or Stage IV Follicular B-Cell Non-Hodgkin's Lymphoma

NCT00460109
COMPLETED Phase 2

Carboplatin and Paclitaxel Albumin-Stabilized Nanoparticle Formulation Followed by Radiation Therapy and Erlotinib in Treating Patients With Stage III Non-Small Cell Lung Cancer That Cannot Be Removed By Surgery

NCT00553462
COMPLETED Phase 2

Epratuzumab and Rituximab in Treating Patients With Previously Untreated Follicular Non-Hodgkin Lymphoma

NCT00553501
TERMINATED Phase 2

Irinotecan and Cediranib in Treating Patients With Metastatic Colorectal Cancer That Did Not Respond to Previous Oxaliplatin, Fluoropyrimidine, and Bevacizumab

NCT00588900
COMPLETED Phase 3

Methylphenidate in Treating Patients With Fatigue Caused by Cancer

NCT00376675
COMPLETED Phase 3

Baclofen-Amitriptyline Hydrochloride-Ketamine Gel in Treating Peripheral Neuropathy Caused by Chemotherapy in Patients With Cancer

NCT00516503
TERMINATED Phase 3

Cryoablation or External-Beam Radiation Therapy in Treating Patients With Painful Bone Metastases

NCT00540969
COMPLETED Phase 2

Temozolomide and Everolimus in Treating Patients With Stage IV Melanoma That Cannot be Removed by Surgery

NCT00521001
TERMINATED Phase 3

Early or Delayed Fludarabine and Rituximab in Treating Patients With Previously Untreated Chronic Lymphocytic Leukemia

NCT00513747
COMPLETED Phase 3

Comparison of Different Types of Surgery in Treating Patients With Stage IA Non-Small Cell Lung Cancer

NCT00499330
COMPLETED Phase 2

Pemetrexed Disodium With or Without Sorafenib as Second-Line Therapy in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer

NCT00454194
COMPLETED

Changes in Breast Density and Blood Hormone Levels in Postmenopausal Women Receiving Anastrozole or Exemestane for Breast Cancer

NCT00516698
COMPLETED Phase 2

Fulvestrant and Bevacizumab in Treating Patients With Metastatic Breast Cancer

NCT00423917
COMPLETED Phase 2

Dasatinib in Treating Patients With Previously Treated Malignant Mesothelioma

NCT00509041
COMPLETED

Studying Tissue Samples From Patients With Stage II Colon Cancer Treated on Clinical Trial CLB-9581

NCT00897429
COMPLETED Phase 2

Gemcitabine and Carboplatin With or Without AZD2171 as First-Line Therapy in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer

NCT00326599
COMPLETED Phase 2

Irinotecan, Oxaliplatin, and Capecitabine as First-Line Therapy in Treating Patients With Metastatic or Unresectable Locally Advanced Small Bowel Cancer

NCT00433550
COMPLETED NA

Collection of Patient-Reported Symptoms and Performance Status Via the Internet

NCT00417040
COMPLETED

Assessing Older Patients With Cancer

NCT00416481
COMPLETED Phase 3

Pilocarpine in Treating Vaginal Dryness in Patients With Breast Cancer

NCT00343382
COMPLETED Phase 3

Vitamin E in Preventing Peripheral Neuropathy Caused by Chemotherapy in Patients Receiving Chemotherapy for Cancer

NCT00363129
COMPLETED

Improving the Selection of Patients With Glioblastoma Multiforme for Treatment With Epidermal Growth Factor Receptor Inhibitor Therapies

NCT00897663
COMPLETED Phase 3

Citalopram in Treating Postmenopausal Women With Hot Flashes

NCT00363909
COMPLETED Phase 2

Carboplatin and ABI-007 in Treating Patients With Stage IV Melanoma That Cannot Be Removed By Surgery

NCT00404235
COMPLETED Phase 3

Topical Sunscreen in Preventing Skin Rash in Patients Receiving Drugs Such as Erlotinib or Cetuximab for Cancer

NCT00362986
COMPLETED Phase 2

Combination Chemotherapy and Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer

NCT00381706
COMPLETED NA

Radiofrequency Ablation in Treating Patients With Stage I Non-Small Cell Lung Cancer

NCT00109876
COMPLETED Phase 3

Stereotactic Radiation Therapy With or Without Whole-Brain Radiation Therapy in Treating Patients With Brain Metastases

NCT00377156
COMPLETED Phase 2

Bortezomib After Combination Chemotherapy, Rituximab, and an Autologous Stem Cell Transplant in Treating Patients With Mantle Cell Lymphoma

NCT00310037
COMPLETED Phase 3

Pyridoxine and Topical Urea/Lactic Acid-Based Cream in Preventing Hand-Foot Syndrome in Patients Receiving Capecitabine for Breast Cancer or Other Cancer

NCT00296036
← Previous Page 4 of 9 Next →

Phase Distribution

PhaseTrial count
Phase 1 26
Phase 2 209
Phase 3 142

Therapeutic Areas

Breast Cancer 19
Lung Cancer 17
Lymphoma 17
Leukemia 9
Colorectal Cancer 9
Prostate Cancer 8
Unspecified Adult Solid Tumor, Protocol Specific 6
Brain and Central Nervous System Tumors 5
Anatomic Stage II Breast Cancer AJCC v8 5
Esophageal Cancer 5

What is open in the Alliance for Clinical Trials in Oncology pipeline

29 recruiting of 446 indexed (7% open); 346 completed (78%).

Phase mix: 142 late (III/IV) vs 235 early (I/II) (early-phase heavy).

Top condition: Breast Cancer (19 trials), 9 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

Alliance for Clinical Trials in Oncology: open-pipeline peers nationwide

Peers matched on 446 registered trials and 7% open enrollment, not the therapeutic-area sidebar.

Alliance for Clinical Trials in Oncology sits at or above the median trial volume and below the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 0100200300400500 5%10%15%20%25% Total trials Recruiting share Alliance for Clinical Trials in OncologyMedical College of WisconsinUniversity of VirginiaChildren's Hospital of PhiladelphiaNovo Nordisk A/SNational Institutes of Health Clinical Center (CC)Insmed IncorporatedNICHD Neonatal Research NetworkHennepin Healthcare Research Institute
Alliance for Clinical Trials in Oncology sits at or above the median trial volume and below the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Alliance for Clinical Trials in Oncology sits at or above the median trial volume and below the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 446 trials (± recruiting share)

Sponsors near 7% open enrollment (± trial volume)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Alliance for Clinical Trials in Oncology page

446 registered trials is a research-attention snapshot, not an endorsement of Alliance for Clinical Trials in Oncology or any single study.

  • 29 of Alliance for Clinical Trials in Oncology's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Breast Cancer is the condition Alliance for Clinical Trials in Oncology studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Breast Cancer trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Alliance for Clinical Trials in Oncology pipeline card: 446 registered trials from official public datasets.Report a data error.